tezepelumab: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
tezepelumab: clinical details
Prescribing considerations
- Initiation should be by a physician experienced in diagnosing and treating the licensed conditions.
- Do not use for acute asthma exacerbations; continue appropriate background treatment.
- Treat a pre-existing serious infection or helminth infection before initiation.
- Assess disease control and clinical benefit periodically.
- Record the product name and batch number for traceability.
Contraindications and cautions
- Hypersensitivity to tezepelumab or any excipient.
- Use caution with previous anaphylaxis, serious infection, helminth infection or hyperprolinaemia.
- Avoid live attenuated vaccines during treatment.
Monitoring
- Monitor for hypersensitivity after administration for an appropriate period, recognising that reactions can be delayed.
- Review disease control, exacerbations, corticosteroid exposure and adherence to background treatment.
- If a serious infection or serious cardiac event develops, interrupt treatment until the acute event has resolved or stabilised.
- Advise patients to report worsening disease, serious infection symptoms and possible cardiac symptoms promptly.
Clinical pharmacology
Human IgG2λ monoclonal antibody against TSLP. It is absorbed after subcutaneous injection, reaches peak serum concentrations over several days and is degraded through proteolytic catabolism rather than hepatic enzyme metabolism. Its elimination half-life is approximately 26 days.
Formulation and product differences
- The selected presentation is a clear-to-opalescent, colourless-to-light-yellow solution in a single-use pre-filled syringe. Follow the syringe-specific Instructions for Use.
tezepelumab preparations and strengths
Injection
Route: Parenteral
Strengths: 210 mg
tezepelumab interactions
Formal interaction studies are limited. Tell the specialist and vaccinator about all medicines and planned vaccines.
Live attenuated vaccines
Avoid during treatment; discuss vaccine timing and suitable alternatives with the clinical team.
Other asthma treatments, including corticosteroids
Clinically important pharmacokinetic interactions are not expected, but corticosteroids must not be stopped abruptly. Any reduction should be supervised.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.